Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Antituberculars" patented technology

SNP (single nucleotide polymorphism) combination, detection method and kit for detecting liver damage susceptible genotype of antitubercular drug

The present invention relates to an SNP (single nucleotide polymorphism) combination, detection method and kit for detecting liver damage susceptible genotype of an antitubercular drug and belongs to the technical field of medical molecular biological diagnosis; the SNP combination includes 7 SNP sites, and nucleotide sequences of the 7 SNP sites are shown sequentially as in SEQ ID NO. 1-7; the present invention also relates to an SNP detection method, comprising PCR (polymerase chain reaction) amplification and double-labeled probe melting curve analytical reaction, and primer pairs and double-labeled probe sequences for detection of the 7 SNP sites are shown as in SEQ ID NO. 8-20. The SNP site combination, detection method and kit provided herein enables quick, accurate, simple and high-throughput detection for a patient's genotype and prediction for the liver damage risk due to the patient using the antitubercular drug.
Owner:THE 309TH HOSPITAL OF CHINESE PEOPLES LIBERATION ARMY +1

Separation screening method for antibiotic antituberculotic plant endophyte

The invention discloses a separation and selection method of antibiotic antitubercular endophyte, which comprises the steps as follows, the preparation of antibiotic antitubercular plant tissue, the surface sterilization and the sterility test, the separation and the purification of the endophyte, the ferment of endogenetic fungi, the ferment of endogenetic bacterium, the process of the zymotic fluid, the process of the thalli, the selection of the effective antibiotic bacterial strains, the selection of the effective antitubercular bacterial strains and the preservation of the strains. The separation and selection method of antibiotic antitubercular endophyte ensures the realization of obtaining the effective antibiotic antitubercular matter from microorganisms, thanks to separation and selection method, a batch of effective bacterial strains are obtained.
Owner:JIANGSU UNIV OF SCI & TECH

Preparation method of medicated slow-release degradable bone scaffold

The invention discloses a preparation method of a medicated slow-release degradable bone scaffold, which comprises the following steps: preparing a biological degradable polyester material (such as PLGA (poly(lactic-co-glycolic acid)) and a loaded antitubercular medicament (such as rifampicin or isoniazide) into PLGA microspheres containing the rifampicin or isoniazide, respectively mixing the PLGA microspheres containing the rifampicin or isoniazide with a biological medical adhesive, and molding with a mold, thus obtaining the medicated slow-release degradable bone scaffold. Having a certain porosity, the medicated slow-release degradable bone scaffold prepared by the preparation method is beneficial to the transportation and exchange of body water, inorganic salt and other nutrient substances and cell metabolism products, thereby being more beneficial to the normal growth and physiologic metabolism of bone cells, and providing an ideal place for the growth of bone tissues; and accompanied by the degradation of the PLGA, the medicament can be continuously released in the focal position and can be kept at a certain concentration, thereby inhibiting the growth of tubercle bacillus, and ultimately degrading the PLGA into carbon dioxide and water which are removed from the body through body metabolism.
Owner:TIANJIN HAIHE HOSPITAL

Application of clinafloxacin amino derivatives and medicinal salts thereof in preparing antitubercular medicaments

The invention discloses an application of clinafloxacin amino derivatives and medicinal salts thereof in preparing antitubercular medicaments. In the structural general formula of the clinafloxacin amino derivatives, R is -(CH2)nNR<1>R<2>, -CH(CH2CH2XCH3)NH2, 2-pyrrolidyl or -OR3; n is 0 or 1; R1 and R2 are separately hydrogen, methyl, 2-hydroxyethyl, (R)-1-ethyl-2-hydroxyethyl, 2-aminoethyl, 3-(dimethylamino)propyl, hydroxyl, amino, methylamino, methoxyl or thiourea group; X is S or SO2; R3 is methyl or isobutyl; the compounds have certain inhibitory effect on standard sensitive strains, clinically isolated sensitive strains and clinically isolated drug-resistant strains of mycobacterium tuberculosis, the antitubercular activity of a part of compounds is stronger than that of ofloxacin and clinafloxacin and weaker than that of moxifloxacin, thus providing a new research direction for the antitubercular medicaments, and being beneficial to clinical treatment of tuberculosis.
Owner:SOUTHWEST UNIVERSITY

Method for extracting live bacteria RNA in Mycobacterium tuberculosis and detection kit thereof

The invention relates to a method for extracting live bacteria RNA in Mycobacterium tuberculosis and a detection kit thereof, and particularly provides a method for extracting live bacteria RNA in Mycobacterium tuberculosis and a detection kit which is used for the live bacteria RNA in the Mycobacterium tuberculosis and is obtained by applying the method and combining fluorescent quantitative PCR technology. The kit can accurately, sensitively and quickly identify dead bacteria and the live bacteria of the Mycobacterium tuberculosis, reduce the cost and shorten the detection time, and more importantly, the kit is the basis of studies such as the diagnosis of tuberculosis, medicinal susceptibility experiments, the monitoring of chemotherapy response, the screening of new antitubercular medicaments, the prevention of the tuberculosis and the like.
Owner:SHANGHAI FOSUN PHARMA (GROUP) CO LTD +1

Compound antitubercular preparation containing gatifloxacin, and preparation method thereof

The invention relates to a new compound antitubercular preparation containing gatifloxacin, and a preparation method thereof. The compound antitubercular preparation comprises rifampicin, isoniazide, pyrazinamide and gatifloxacin. Each unit of preparation contains 100-150mg of rifampicin, 60-120mg of isoniazide, 200-400mg of pyrazinamide and 100-200mg of gatifloxacin. The addition of gatifloxacin in the preparation can shorten the course of treatment of tuberculosis and improve the treatment effect; and degradation of the rifampicin can be reduced through dry method granulating tabletting, thus improving the bioavailability of rifampicin and improving the curative effect of the medicament. The compound preparation can be prepared into common tablets, double-layer coated-core tablets or pellet-core tablets.
Owner:SHENYANG PHARMA UNIVERSITY

Fluoroquinolone comprising 7-(3-amino-4-oximido)-1-piperidyl substitutional group and application of composition thereof

The invention relates to new application of a fluoroquinolone compound comprising a 7-(3-amino-4-oximido)-1-piperidyl substitutional group, in particular to application of 1-cyclopropyl-6-flurine-8-methoxyl-7-[(3-amino-4-methyl / ethyl oximido) piperidyl-1-group]-1,4-dihydro-4-oxo quinoline-3-carboxylic acid, or medicinal salt, hydrate and composition thereof in curing tuberculosis. Compared with the conventional clinic first-line antitubercular medicament (such as rifampicin) and a second-line antitubercular fluoroquinolones medicament (such as ciprofloxacin and the like), the fluoroquinolone compound has more excellent antitubercular mycobacteria activity.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI +1

Carrier bacterin of attenuated typhoid bacterium of carrying tubercle branch bacillus Ag85B

InactiveCN101049508AImprove the ability to synthesize IgAEffective cellular immunityBacterial antigen ingredientsBacteriaMicrobiologyMycobacterium
An attenuated Salmonella typhi carrier vaccine carrying tubercular mycobacterium Ag85B is prepared through preparing prokaryotic recombinant expression plasmid pGEX-Ag85B, configuring eukaryotic recombinant expression plasmid pVAX1-Ag85B, and preparing said antitubercular vaccine. It can be orally taken.
Owner:WUHAN UNIV

Antitubercular alkaloid

A derivative of β-carboline alkaloid harmine, 10,12-diheptanoyl-11-hydroxy-3-methyl-β-carboline, prepared by a Friedel-Crafts acylation of harmine is reported as a novel potent antitubercular drug.
Owner:BEGUM SABRA +2

Antimycobacterial pharmaceutical composition

An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.
Owner:LUPIN LTD

Application of radiolabeled irradiation anthranone or naphtho dianthrone compounds to preparation of antitubercular medicine

The invention relates to a radiolabeled irradiation anthranone or naphtho dianthrone compound, which has the specific affinity capability in biosome necrotic tissues and simultaneously comprises chemical elements or isotopes with unstable nucleus. Radiation can be emitted out in a period when the compound is decayed to the stable state, and the radiation is sufficient to damage the adjacent tubercle bacillus for target radiation treatment, so the antitubercular treatment possibility is improved. The compound has a special advantage that the drug resistance tuberculosis can be treated through single-time or multi-time dosage of the radiolabeled irradiation anthranone or naphtha dianthrone compound.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE

Screening method of drug for resisting retention-state mycobacterium tuberculosis

The invention discloses a screening method of a drug for resisting retention-state mycobacterium tuberculosis, which utilizes the change of the light absorption value of an enzyme-labeling instrumentdetection reaction system to judge the inhibition function to the activity of protein kinase G in a sample by adding the sample to be measured into an enzyme activity measuring system, thereby screening a drug for resisting the retention-state mycobacterium tuberculosis. The screening method selects the protein kinase G as a target point and is different from the pervious antitubercular drug whichmainly aims at bacteria with active growth and propagation. The invention aims at solving the difficult problem of long-term incubative infection of mycobacterium tuberculosis by aiming at bacteria which exists in host cells for a long time in a retention state.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Antimicrobial and antitubercular compounds

Infections caused by Mycobacterium tuberculosis kill more than 1.8 million people each year. While the persistence of this pathogenic bacterial species and the emergence of multidrug resistant strains have created an urgent need for new TB therapies, a new TB-specific drug has not been developed in over 40 years. The disclosure herein provides short and scalable syntheses of small molecules, and small molecules as new therapeutics for eradicating this life threatening pathogen.
Owner:THE TRUSTEES FOR PRINCETON UNIV

Antitubercular injection and preparation method thereof

ActiveCN101664433APromote positive energy recoveryImprove defense function defectsAntibacterial agentsPharmaceutical delivery mechanismDiseaseSide effect
The invention relates to an antitubercular injection and a preparation method thereof. The antitubercular injection comprises the following traditional Chinese medicinal materials: panax notoginseng,astragalus, drynaria, olibanum and myrrh as well as glucose containing auxiliary materials for injection, polysorbate and benzyl alcohol and is prepared by the following process steps: preparing a concentrated solution, centrifugally separating, heating, dissolving, finely filtering, and the like. The invention solves the technical problems of unstable product quality and great clinical side effect caused by low production efficiency, poor medicinal liquid clarity, overstandard endotoxin, and the like due to easy membrane block and penetration in the production process of the traditional Chinese medicinal injection. The antitubercular injection has the functions of supplementing qi, nourishing the blood, tonifying the kidney, strengthening the bones and promoting blood circulation by removing blood stasis and is suitable for various tuberculosis, such as pulmonary tuberculosis, osteoarticular tuberculosis, lymphatic tuberculosis, and the like as well as nodular leprosy and other diseases.
Owner:张瑛

Semi-synthetic aminoglycoside antibiotic, preparation method and medicine composition thereof

The invention discloses a semi-synthetic aminoglycoside antibiotic of 1-N-acetyl micronomicin, and pharmaceutically acceptable salt and a preparation method thereof. The preparation method of 1-N-acetyl micronomicin comprises the following steps: the formylation protection is carried out on C2'-NH2 and C3-NH2 of micronomicin basic groups, the 3,-2-two-N-formoxyl micronomicin, the acetylation reaction is then carried out to obtain 1-N-acetyl-3,-2-two-N-formoxyl micronomicin, the obtained products are subject to hydrolysis reaction in alkali solution, and the 1-N-acetyl micronomicin is obtained through formylation protection for removing 2'-NH2 and 3-NH2. The 1-N-acetyl micronomicin has the advantages that in-vitro antitubercular bacteria and antibiotic activity experiments prove that the 1-N-acetyl micronomicin has higher antibiotic activity to mycobacterium tuberculosis gram-positive bacteria and negative bacteria, in addition, the toxicity of medicine on ears and kidneys is greatly reduced, and higher clinical application value is realized.
Owner:CHANGZHOU FANGYUAN PHARMA

Antitubercular inhibitor screened target gene Rv2498c and application thereof

The invention belongs to the technical field of drug molecules and in particular relates to an application of mycobacterium tuberculosis gene Rv2498c in the antitubercular inhibitor screened target. The application is characterized in that the gene has the nucleotide sequence shown as SEQ. ID NO:1, and the encoded protein has the sequence of SEQ. ID NO:2. A virtual screening method is utilized, aiming at a natural primer activity center of Rv2498c, 20 small molecule compounds with a high affinity with the natural primer binding sites of the Rv2498c are screened from a small molecule compound database by operating a molecular docking program, two antibacterial compounds such as 66# triazine compound and a 70# quinoxaline compound are obtained, the 66# triazine compound has the name of 4-aniline-6-piperidine-1-yl-1-1,3,5-triazine-2(1H)-hydrazone; and the 70# quinoxaline compound has the name of N-allyl-N-[3-(allylimine)-1,4-dihydro-2-quinoxalineyl]amine). The antibacterial effects of the two compounds in mycobacterium tuberculosis are evaluated.
Owner:HUAZHONG AGRI UNIV

Compound antitubercular preparation containing gatifloxacin, and preparation method thereof

The invention relates to a new compound antitubercular preparation containing gatifloxacin, and a preparation method thereof. The compound antitubercular preparation comprises rifampicin, isoniazide, pyrazinamide and gatifloxacin. Each unit of preparation contains 100-150mg of rifampicin, 60-120mg of isoniazide, 200-400mg of pyrazinamide and 100-200mg of gatifloxacin. The addition of gatifloxacin in the preparation can shorten the course of treatment of tuberculosis and improve the treatment effect; and degradation of the rifampicin can be reduced through dry method granulating tabletting, thus improving the bioavailability of rifampicin and improving the curative effect of the medicament. The compound preparation can be prepared into common tablets, double-layer coated-core tablets or pellet-core tablets.
Owner:SHENYANG PHARMA UNIVERSITY

Application of radiolabeled irradiation anthranone or naphtho dianthrone compounds to preparation of antitubercular medicine

The invention relates to a radiolabeled irradiation anthranone or naphtho dianthrone compound, which has the specific affinity capability in biosome necrotic tissues and simultaneously comprises chemical elements or isotopes with unstable nucleus. Radiation can be emitted out in a period when the compound is decayed to the stable state, and the radiation is sufficient to damage the adjacent tubercle bacillus for target radiation treatment, so the antitubercular treatment possibility is improved. The compound has a special advantage that the drug resistance tuberculosis can be treated through single-time or multi-time dosage of the radiolabeled irradiation anthranone or naphtha dianthrone compound.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE

Miao medicine 103 deer-blood element medicine for resisting multi-drug resistant pulmonary tuberculosis and preparation method of 103 deer-blood element

The invention discloses a miao medicine 103 deer sanguinin multi-drug resistance tuberculosis drug. Fresh deer blood or dry deer blood is added with powdery 103 deer sanguinin biodegraded by 103 protease of scolopendra subspinipes multilans or 103 protease of other animals, plants, bacteria and fungi; and the mixture is added with rhizoma bletillae, water, notoginseng and auxiliary materials to form the tuberculosis drug. The invention also discloses a method for preparing 103 deer sanguinin. The drug can rapidly improve human immune function and physical quality and achieve functions of autologous antibiosis and sterilization, thereby rapidly curing tuberculosis and multi-drug resistance tuberculosis; and the drug has little dosage, short treatment course and extremely low recurrence rate. A product is matched with a few western antitubercular drugs for combined treatment, can remarkably reduce toxicity and side effect of western drugs, has better effect on multi-drug resistance tuberculosis and achieves huge social effect and economic benefit for improving the status of Chinese medicine for resisting tuberculosis disease.
Owner:贵州百灵企业集团乾元制药有限公司

Antimycobacterial pharmaceutical composition

An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereofand an amount of one or more first line antitubercular drugs.
Owner:LUPIN LTD

1, 2, 4-triazole derivatives and their anti mycobacterial activity

Invention provides antitubercular compounds selected from propargylated 1,2,3 triazoles of Formula I, wherein, X is sulfur (S) or a sulphone (A), n, m represent independently an integer O or 1, with the provision that when ‘n’ is 1, ‘m’ is 1; R1 is hydrogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group; halogen; or aryl group optionally substituted with —OCH3, halogen, and nitro; R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is C1-C6 alkyl optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl allyl or propargyl groups consisting of 1 to 6 carbon atoms; with the provision that when ‘m’ is 1, and ‘n’ is zero; R1 is selected from the group consisting of hydrogen, halogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group or aryl group optionally substituted with —OCH3, halogen, and nitro, R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is selected from the group consisting of halogen, C1-C6 linear or branched alkyl group optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, wherein the heterocyclic ring may further be substituted with halogen, alkyl, arylalkyl.
Owner:COUNCIL OF SCI & IND RES

Isoniazid thiadiazine thione derivative

InactiveCN101747331AIncrease fat solubilityIncreased capacity for highly dispersible formulationsAntibacterial agentsOrganic active ingredientsSolubilityLipid formation
The invention discloses an isoniazid thiadiazine thione derivative, which solves the problem that the existing derivative has poor lipid solubility of active ingredient, and can not dissolve in water or can not highly disperse. The structure of the derivative can be presented by INH-THTT-R-THTT-INH, wherein ING represents the structure of isoniazid of antitubercular drug, THTT is a ring structure, and R is linear chain, non-linear chain or annular alkyl compound containing two primary amines (including alkyl structures of different substituent groups). The derivative can be prepared into highly-dispersed drug delivery system, including the dosage form of liposome, solid lipid nanospheres, niosomes, micro emulsion and the like. The derivative can not only improve the lipid solubility of isoniazid, but also hydrolyze and release isoniazid active compound in vivo, increases the penetrability of isoniazid cell, reduces the tolerance of isoniazid during therapy and improves the curative effect.
Owner:成都格蓝洋生物医药科技有限公司

Application of tuberculosis chemotherapeutic drugs in treatment of psoriasis

InactiveCN109288839AChanging the treatment philosophySmall toxicityAntibacterial agentsOrganic active ingredientsPsoriasis patientConsolidation therapy
Belonging to the field of medical technology, the invention discloses a new use of tuberculosis chemotherapeutic drugs, i.e. application of tuberculosis chemotherapeutic drugs in treatment of psoriasis. According to the invention, through oral administration of isoniazide, rifampicin, and any one of the antitubercular drugs sodium aminosalicylate, pyrazinamide, ethambutol, moxifloxacin hydrochloride and levofloxacin hydrochloride by psoriasis patients, 95% or more of the psoriasis patients can have obviously alleviated symptoms in 6-10 weeks and can achieve recovery in 10-18 weeks, and after recovery, the consolidation therapy to the 28th week is a treatment cycle, and relapse hardly occurs, thus reaching the purpose of radical treatment of psoriasis. If psoriasis is caused by mycobacterium tuberculosis infection, the invention starts from the cause of psoriasis, completely changes the treatment concept of original psoriasis treatment drugs and achieves etiological treatment. Moreover,the tuberculosis chemotherapeutic drugs involved in the invention are cheap, thus alleviating the psoriasis patients' economic burden caused by long-term medication of psoriasis patients.
Owner:郭长安

1, 2, 4-triazole derivatives and their anti mycobacterial activity

InactiveUS8865910B2Antibacterial agentsBiocideAnti mycobacterialTriazole derivatives
Invention provides antitubercular compounds selected from propargylated 1,2,3 triazoles of Formula I, wherein, X is sulfur(S) or a sulphone (A), n, m represent independently an integer O or 1, with the provision that when ‘n’ is 1, ‘m’ is 1; R1 is hydrogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group; halogen; or aryl group optionally substituted with —OCH3, halogen, and nitro; R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is C1-C6 alkyl optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl allyl or propargyl groups consisting of 1 to 6 carbon atoms; with the provision that when ‘m’ is 1, and ‘n’ is zero; R1 is selected from the group consisting of hydrogen, halogen; C1-C6 linear or branched alkyl group optionally substituted with aryl group or aryl group optionally substituted with —OCH3, halogen, and nitro, R2 and R3 are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted with heterocyclic ring of 5 to 6 ring atoms containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, which may be substituted with alkyl, arylalkyl, linear or branched alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or allyl or propargyl groups consisting of 1 to 6 carbon atoms; Z is selected from the group consisting of halogen, C1-C6 linear or branched alkyl group optionally substituted with heterocyclic ring of 1 to 6 ring atoms, containing one to three hetero atoms selected from oxygen, sulfur, nitrogen, wherein the heterocyclic ring may further be substituted with halogen, alkyl, arylalkyl.
Owner:COUNCIL OF SCI & IND RES

Application of clinafloxacin amino derivatives and medicinal salts thereof in preparing antitubercular medicaments

The invention discloses an application of clinafloxacin amino derivatives and medicinal salts thereof in preparing antitubercular medicaments. In the structural general formula of the clinafloxacin amino derivatives, R is -(CH2)nNR<1>R<2>, -CH(CH2CH2XCH3)NH2, 2-pyrrolidyl or -OR3; n is 0 or 1; R1 and R2 are separately hydrogen, methyl, 2-hydroxyethyl, (R)-1-ethyl-2-hydroxyethyl, 2-aminoethyl, 3-(dimethylamino)propyl, hydroxyl, amino, methylamino, methoxyl or thiourea group; X is S or SO2; R3 is methyl or isobutyl; the compounds have certain inhibitory effect on standard sensitive strains, clinically isolated sensitive strains and clinically isolated drug-resistant strains of mycobacterium tuberculosis, the antitubercular activity of a part of compounds is stronger than that of ofloxacin and clinafloxacin and weaker than that of moxifloxacin, thus providing a new research direction for the antitubercular medicaments, and being beneficial to clinical treatment of tuberculosis.
Owner:SOUTHWEST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products